Get the Stockscreener App
33.75
0.51%
0.17
Kiniksa Pharmaceuticals International Plc stock is traded at $33.75, with a volume of 356.17K.
It is up +0.51% in the last 24 hours and up +22.11% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$33.58
Open:
$33.76
24h Volume:
356.17K
Relative Volume:
0.46
Market Cap:
$1.47B
Revenue:
$384.10M
Net Income/Loss:
$-9.07M
P/E Ratio:
-241.07
EPS:
-0.14
Net Cash Flow:
$11.10M
1W Performance:
+1.11%
1M Performance:
+22.11%
6M Performance:
+68.58%
1Y Performance:
+28.77%
1-Day Range:
$33.53
$34.24
1-Week Range:
$32.90
$34.55
52-Week Range:
$17.82
$34.55
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Compare KNSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
33.75 | 2.50B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month HighHere's What Happened - MarketBeat
Deutsche Bank AG Has $8.76 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $1,600,786.80 in Stock - MarketBeat
Thomas Malley Sells 78,233 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Thomas Malley Sells 50,129 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Is Kiniksa Pharmaceuticals Ltd. stock entering bullish territoryWeekly Market Outlook & Free Real-Time Volume Trigger Notifications - Newser
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Published on: 2025-08-17 04:40:11 - Newser
Connor Clark & Lunn Investment Management Ltd. Buys 92,797 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas - Barchart.com
Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Insider Sells 29,325 Shares of Stock - MarketBeat
Eben Tessari Sells 138,614 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Michael R. Megna Sells 17,000 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Sells $621,259.21 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighShould You Buy? - MarketBeat
BIT Capital GmbH Takes $264,000 Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
J.P. Morgan Maintains Buy Rating on Kiniksa Pharmaceuticals with $55 Price Target - AInvest
Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen - Defense World
Kiniksa Pharmaceuticals surges 11.01% on Arcalyst's market penetration - AInvest
Victory Capital Management Inc. Makes New Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? - MSN
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malley Thomas | Director |
Aug 14 '25 |
Option Exercise |
14.89 |
78,233 |
1,165,028 |
90,779 |
| Malley Thomas | Director |
Aug 13 '25 |
Option Exercise |
10.07 |
50,129 |
504,936 |
62,675 |
| Malley Thomas | Director |
Aug 12 '25 |
Option Exercise |
2.94 |
49,407 |
145,146 |
61,953 |
| Malley Thomas | Director |
Aug 14 '25 |
Sale |
33.09 |
78,233 |
2,588,730 |
12,546 |
| Malley Thomas | Director |
Aug 13 '25 |
Sale |
33.32 |
50,129 |
1,670,298 |
12,546 |
| Malley Thomas | Director |
Aug 12 '25 |
Sale |
32.40 |
49,407 |
1,600,787 |
12,546 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):